Click here to listen.<\/a><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"Dr. Ahmed Enayetallah, joins Cell & Gene: The Podcast Host, Erin Harris, to discuss the company’s phase I clinical trial for Parkinson\u2019s disease, which continues to show positive trends at 18 months. They cover the important role induced pluripotent stem cells’ (iPSCs) play in […]<\/p>\n","protected":false},"author":2,"featured_media":8909,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[59],"tags":[56,61,62],"class_list":["post-8908","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-podcasts","tag-neurology","tag-parkinsons-disease","tag-podcast"],"acf":[],"yoast_head":"\n
Cell & Gene The Podcast: Inside BlueRock Therapeutics' Parkinson's Disease Trial - BlueRock Therapeutics LP<\/title>\n<meta name=\"description\" content=\"Dr. Ahmed Enayetallah, joins Cell & Gene: The Podcast Host, Erin Harris, to discuss the company's phase I clinical trial for Parkinson\u2019s disease, which continues to show positive trends at 18 months. They cover the important role induced pluripotent stem cells' (iPSCs) play in the trial, and they also discuss the company's investigational cell therapy, bemdaneprocel.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.bluerocktx.com\/cell-gene-the-podcast-inside-bluerock-therapeutics-parkinsons-disease-trial\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cell & Gene The Podcast: Inside BlueRock Therapeutics' Parkinson's Disease Trial - BlueRock Therapeutics LP\" \/>\n<meta property=\"og:description\" content=\"Dr. Ahmed Enayetallah, joins Cell & Gene: The Podcast Host, Erin Harris, to discuss the company's phase I clinical trial for Parkinson\u2019s disease, which continues to show positive trends at 18 months. They cover the important role induced pluripotent stem cells' (iPSCs) play in the trial, and they also discuss the company's investigational cell therapy, bemdaneprocel.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.bluerocktx.com\/cell-gene-the-podcast-inside-bluerock-therapeutics-parkinsons-disease-trial\/\" \/>\n<meta property=\"og:site_name\" content=\"BlueRock Therapeutics LP\" \/>\n<meta property=\"article:published_time\" content=\"2024-04-25T18:18:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-05-16T22:35:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.bluerocktx.com\/wp-content\/uploads\/2024\/04\/23_12_CGPodcast_1280x720_Ep74.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"720\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"BlueRock Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"BlueRock Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.bluerocktx.com\/cell-gene-the-podcast-inside-bluerock-therapeutics-parkinsons-disease-trial\/\",\"url\":\"https:\/\/www.bluerocktx.com\/cell-gene-the-podcast-inside-bluerock-therapeutics-parkinsons-disease-trial\/\",\"name\":\"Cell & Gene The Podcast: Inside BlueRock Therapeutics' Parkinson's Disease Trial - BlueRock Therapeutics LP\",\"isPartOf\":{\"@id\":\"https:\/\/www.bluerocktx.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.bluerocktx.com\/cell-gene-the-podcast-inside-bluerock-therapeutics-parkinsons-disease-trial\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.bluerocktx.com\/cell-gene-the-podcast-inside-bluerock-therapeutics-parkinsons-disease-trial\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.bluerocktx.com\/wp-content\/uploads\/2024\/04\/23_12_CGPodcast_1280x720_Ep74.jpg\",\"datePublished\":\"2024-04-25T18:18:39+00:00\",\"dateModified\":\"2024-05-16T22:35:50+00:00\",\"author\":{\"@id\":\"https:\/\/www.bluerocktx.com\/#\/schema\/person\/7bce67a9ee8dcf888329288a28761057\"},\"description\":\"Dr. Ahmed Enayetallah, joins Cell & Gene: The Podcast Host, Erin Harris, to discuss the company's phase I clinical trial for Parkinson\u2019s disease, which continues to show positive trends at 18 months. They cover the important role induced pluripotent stem cells' (iPSCs) play in the trial, and they also discuss the company's investigational cell therapy, bemdaneprocel.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.bluerocktx.com\/cell-gene-the-podcast-inside-bluerock-therapeutics-parkinsons-disease-trial\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.bluerocktx.com\/cell-gene-the-podcast-inside-bluerock-therapeutics-parkinsons-disease-trial\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.bluerocktx.com\/cell-gene-the-podcast-inside-bluerock-therapeutics-parkinsons-disease-trial\/#primaryimage\",\"url\":\"https:\/\/www.bluerocktx.com\/wp-content\/uploads\/2024\/04\/23_12_CGPodcast_1280x720_Ep74.jpg\",\"contentUrl\":\"https:\/\/www.bluerocktx.com\/wp-content\/uploads\/2024\/04\/23_12_CGPodcast_1280x720_Ep74.jpg\",\"width\":1280,\"height\":720,\"caption\":\"multicolor title graphic for cell & gene the podcast featuring BlueRock Therapeutics\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.bluerocktx.com\/cell-gene-the-podcast-inside-bluerock-therapeutics-parkinsons-disease-trial\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.bluerocktx.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cell & Gene The Podcast: Inside BlueRock Therapeutics’ Parkinson’s Disease Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.bluerocktx.com\/#website\",\"url\":\"https:\/\/www.bluerocktx.com\/\",\"name\":\"BlueRock Therapeutics LP\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.bluerocktx.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.bluerocktx.com\/#\/schema\/person\/7bce67a9ee8dcf888329288a28761057\",\"name\":\"BlueRock Therapeutics\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.bluerocktx.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/154b53ac9f1feafa6f14d0efa17a4fdb?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/154b53ac9f1feafa6f14d0efa17a4fdb?s=96&d=mm&r=g\",\"caption\":\"BlueRock Therapeutics\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cell & Gene The Podcast: Inside BlueRock Therapeutics' Parkinson's Disease Trial - BlueRock Therapeutics LP","description":"Dr. Ahmed Enayetallah, joins Cell & Gene: The Podcast Host, Erin Harris, to discuss the company's phase I clinical trial for Parkinson\u2019s disease, which continues to show positive trends at 18 months. They cover the important role induced pluripotent stem cells' (iPSCs) play in the trial, and they also discuss the company's investigational cell therapy, bemdaneprocel.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.bluerocktx.com\/cell-gene-the-podcast-inside-bluerock-therapeutics-parkinsons-disease-trial\/","og_locale":"en_US","og_type":"article","og_title":"Cell & Gene The Podcast: Inside BlueRock Therapeutics' Parkinson's Disease Trial - BlueRock Therapeutics LP","og_description":"Dr. Ahmed Enayetallah, joins Cell & Gene: The Podcast Host, Erin Harris, to discuss the company's phase I clinical trial for Parkinson\u2019s disease, which continues to show positive trends at 18 months. They cover the important role induced pluripotent stem cells' (iPSCs) play in the trial, and they also discuss the company's investigational cell therapy, bemdaneprocel.","og_url":"https:\/\/www.bluerocktx.com\/cell-gene-the-podcast-inside-bluerock-therapeutics-parkinsons-disease-trial\/","og_site_name":"BlueRock Therapeutics LP","article_published_time":"2024-04-25T18:18:39+00:00","article_modified_time":"2024-05-16T22:35:50+00:00","og_image":[{"width":1280,"height":720,"url":"https:\/\/www.bluerocktx.com\/wp-content\/uploads\/2024\/04\/23_12_CGPodcast_1280x720_Ep74.jpg","type":"image\/jpeg"}],"author":"BlueRock Therapeutics","twitter_card":"summary_large_image","twitter_misc":{"Written by":"BlueRock Therapeutics","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.bluerocktx.com\/cell-gene-the-podcast-inside-bluerock-therapeutics-parkinsons-disease-trial\/","url":"https:\/\/www.bluerocktx.com\/cell-gene-the-podcast-inside-bluerock-therapeutics-parkinsons-disease-trial\/","name":"Cell & Gene The Podcast: Inside BlueRock Therapeutics' Parkinson's Disease Trial - BlueRock Therapeutics LP","isPartOf":{"@id":"https:\/\/www.bluerocktx.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.bluerocktx.com\/cell-gene-the-podcast-inside-bluerock-therapeutics-parkinsons-disease-trial\/#primaryimage"},"image":{"@id":"https:\/\/www.bluerocktx.com\/cell-gene-the-podcast-inside-bluerock-therapeutics-parkinsons-disease-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/www.bluerocktx.com\/wp-content\/uploads\/2024\/04\/23_12_CGPodcast_1280x720_Ep74.jpg","datePublished":"2024-04-25T18:18:39+00:00","dateModified":"2024-05-16T22:35:50+00:00","author":{"@id":"https:\/\/www.bluerocktx.com\/#\/schema\/person\/7bce67a9ee8dcf888329288a28761057"},"description":"Dr. Ahmed Enayetallah, joins Cell & Gene: The Podcast Host, Erin Harris, to discuss the company's phase I clinical trial for Parkinson\u2019s disease, which continues to show positive trends at 18 months. They cover the important role induced pluripotent stem cells' (iPSCs) play in the trial, and they also discuss the company's investigational cell therapy, bemdaneprocel.","breadcrumb":{"@id":"https:\/\/www.bluerocktx.com\/cell-gene-the-podcast-inside-bluerock-therapeutics-parkinsons-disease-trial\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.bluerocktx.com\/cell-gene-the-podcast-inside-bluerock-therapeutics-parkinsons-disease-trial\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.bluerocktx.com\/cell-gene-the-podcast-inside-bluerock-therapeutics-parkinsons-disease-trial\/#primaryimage","url":"https:\/\/www.bluerocktx.com\/wp-content\/uploads\/2024\/04\/23_12_CGPodcast_1280x720_Ep74.jpg","contentUrl":"https:\/\/www.bluerocktx.com\/wp-content\/uploads\/2024\/04\/23_12_CGPodcast_1280x720_Ep74.jpg","width":1280,"height":720,"caption":"multicolor title graphic for cell & gene the podcast featuring BlueRock Therapeutics"},{"@type":"BreadcrumbList","@id":"https:\/\/www.bluerocktx.com\/cell-gene-the-podcast-inside-bluerock-therapeutics-parkinsons-disease-trial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.bluerocktx.com\/"},{"@type":"ListItem","position":2,"name":"Cell & Gene The Podcast: Inside BlueRock Therapeutics’ Parkinson’s Disease Trial"}]},{"@type":"WebSite","@id":"https:\/\/www.bluerocktx.com\/#website","url":"https:\/\/www.bluerocktx.com\/","name":"BlueRock Therapeutics LP","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.bluerocktx.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.bluerocktx.com\/#\/schema\/person\/7bce67a9ee8dcf888329288a28761057","name":"BlueRock Therapeutics","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.bluerocktx.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/154b53ac9f1feafa6f14d0efa17a4fdb?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/154b53ac9f1feafa6f14d0efa17a4fdb?s=96&d=mm&r=g","caption":"BlueRock Therapeutics"}}]}},"_links":{"self":[{"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/posts\/8908"}],"collection":[{"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/comments?post=8908"}],"version-history":[{"count":3,"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/posts\/8908\/revisions"}],"predecessor-version":[{"id":8939,"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/posts\/8908\/revisions\/8939"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/media\/8909"}],"wp:attachment":[{"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/media?parent=8908"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/categories?post=8908"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/tags?post=8908"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}